Yin yang 1 and raf-1 kinase inhibitory protein status in hepatocellular carcinoma: Future perspectives

Forum on Immunopathological Diseases and Therapeutics

Volumn 1, Issue 1-2, 2010, Pages 97-114

  D'Alessandro, Natale ^a   Giannitrapani, Lydia ^a   Labbozzetta, Manuela ^a   Poma, Paola ^a   Inguglia, Luigi ^a   Florena, Ada Maria ^a   Porcasi, Rossana ^a   Cervello, Melchiorre ^b   Montalto, Giuseppe ^a   Notarbartolo, Monica ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy   (Italy)

Author keywords

Hepatocellular carcinoma; Nuclear factor kappa B; Raf 1 kinase inhibitor protein; Sorafenib; Yin yang 1; YY1 associated protein

Indexed keywords

CURCUMIN; DEHYDROXYMETHYLEPOXYQUINOMICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; SORAFENIB; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR YY1;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL NUCLEUS; DRUG TARGETING; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

EID: 79953811284     PISSN: 21518017     EISSN: 21518025     Source Type: Journal    
DOI: 10.1615/ForumImmunDisTher.v1.i1-2.70     Document Type: Article

References (70)

1. El-Seraq HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-76. (Pubitemid 46890874)
2. Sandhu DS, Tharavil VS, Lai JP, Roberts LR. Treatment options for hepatocellular carcinoma. Expert Rev. Gastroenterol Hepatol. 2008;2:81-92.
3. Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials. Ann Oncol. 1997;8:117-36. (Pubitemid 27112878)
4. Wong CM, Ng IO. Molecular pathogenesis of hepatocellular carcinoma. Liver Int. 2008;28:160-74. (Pubitemid 351201031)
5. D'Alessandro N, Poma P, Montalto G. Multifactorial nature of hepatocellular carcinoma drug resistance: Could plant polyphenols be helpful? World J Gastroenterol. 2007;13:2037-43. (Pubitemid 46795838)
6. Ng IO, Liu CL, Fan ST, Ng M. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response. Am J Clin Pathol. 2000;113:355-63. (Pubitemid 30217382)
7. Chou YY, Cheng AL, Hsu HC. Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: Clinical correlation. J Gastroenterol Hepatol. 1997;12:569-75.
8. Lai EC, Choi TK, Cheng CH, Mok FP, Fan ST, Tan ES, Wong J. Doxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamil. Cancer. 1990;66:1685-7. (Pubitemid 20381199)
9. Fabregat J. Dysregulation of apoptosis in hepatocellular carcinoma cells. World J. Gastroenterol. 2009;15:513-20.
10. Hussain SP, Schwank J, Staib F, Wang XW, Harris CC. TP53 mutations and hepatocellular carcinoma: Insights into the etiology and pathogenesis of liver cancer. Oncogene. 2007;26:2166-76. (Pubitemid 46536641)
11. Du J, Liang X, Liu Y, Qu Z, Gao L, Han L, Liu S, Cui M, Shi Y, Zhang Z, Yu L, Cao L, Ma C, Zhang L, Chen Y, Sun W. Hepatitis B virus core protein inhibits TRAIL-induced apoptosis of hepatocytes by blocking DR5 expression. Cell Death Differ. 2009;16:219-29.
12. Yoshida T, Hisamoto T, Akiba J, Koga H, Nakamura K, Tokunaga Y, Hanada S, Kumemura H, Maeyama M, Harada M, Ogata H, Yano H, Kojiro M, Ueno T, Yoshimura A, Sata M. Spreds, inhibitors of the Ras/ ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene. 2006;25:6056-66. (Pubitemid 44562404)
13. Calvisi DF, Pinna F, Meloni F, Ladu S, Pellegrino R, Sini M, Daino L, Simile MM, De Miglio MR, Virdis P, Frau M, Tomasi ML, Seddaiu MA, Muroni MR, Feo F, Pascale RM. Dual-specificity phosphatase 1 ubiquitination in extracellular signal-regulated kinase-mediated control of growth in human hepatocellular carcinoma. Cancer Res. 2008;68:4192-200.
14. Kim YC, Song KS, Yoon G, Nam MJ, Ryu WS. Activated ras oncogene collaborates with HBx gene of hepatitis B virus to transform cells by suppressing HBx-mediated apoptosis. Oncogene. 2001;20:16-23. (Pubitemid 32142334)
15. Liu P, Kimmoun E, Legrand A, Sauvanet A, Degott C, Lardeux B, Bernuau D. Activation of NF-kappaB, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas. J Hepatol. 2002;37:63-71. (Pubitemid 34713056)
16. Chiao PJ, Na R, Niu J, Sclabas GM, Dong Q, Curley SA. Role of Rel/ NF-kappaB transcription factors in apoptosis of human hepatocellular carcinoma cells. Cancer. 2002;95:1696-705.
17. Chan CF, Yau TO, Jin DY, Wong CM, Fan ST, Ng IO. Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma. Clin Cancer Res. 2004;10:4140-9. (Pubitemid 38812494)
18. Arsura M, Cavin LG. Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett. 2005;229: 157-69.
19. Vainer GW, Pilarsky E, Ben-Neriah Y. Contradictory functions of NFkappaB in liver physiology and cancer. Cancer Lett. 2008;267:182-8.
20. Miyoshi A, Kitajima Y, Kido S, Shimonishi T, Matsuyama S, Kitahara K, Miyazaka K. Snail accelerates cancer invasion by upregulating MMP expression and is associated with poor prognosis of hepatocellular carcinoma. Br J Cancer. 2005;92:252-8. (Pubitemid 40343137)
21. Lee TK, Poon RT, Yuen AP, Ling MT, Kwok WK, Wang XH, Wong YC, Guan XY, Man K, Chau KL, Fan ST. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial- mesenchymal transition. Clin Cancer Res. 2006;12:5369-76. (Pubitemid 44497250)
22. Fischer AN, Fuchs E, Mikula M, Huber H, Beug H, Mikulits W. PDGF essentially links TGF-beta signaling to nuclear beta-catenin accu mulation in hepatocellular carcinoma progression. Oncogene. 2007; 26:3395-405. (Pubitemid 46788880)
23. Alison MR. Liver stem cells: Implications for hepatocarcinogenesis. Stem Cell Rev. 2005;1:253-60. (Pubitemid 41737102)
24. Lee TKW, Castilho A, Ma S, Ng IOL. Liver cancer stem cells: Implications for a new therapeutic target. Liver Int. 2009;29:955-65.
25. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
26. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
27. Villanueva A, Toffanin S, Llovet JM. Linking molecular classification of hepatocellular carcinoma and personalized medicine: Preliminary steps. Curr Opin Oncol. 2008;20:444-53.
28. Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: Structure, function, and therapeutic implications in cancer biology. Oncogene. 2006;25:1125-42.
29. Wang CC, Chen JJ, Yang PC. Multifunctional transcription factor YY1: A therapeutic target in human cancer? Expert Opin Ther Targets. 2006;10:253-66.
30. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, Fee F, Katsanakis KD, Rose DW, Mischak H, Sedivy JM, Kolch W. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature. 1999;401:173-7. (Pubitemid 29436321)
31. Odabaei G, Chatteriee D, Jazirehi AR, Goodglick L, Yeung K, Bonavida B. Raf-1 kinase inhibitor protein: Structure, function, regulation of cell signalling, and pivotal role in apoptosis. Adv Cancer Res. 2004;91:169-200. (Pubitemid 39140959)
32. Klysik J, Theroux SJ, Sedivy JM, Moffit JS, Boekelheide K. Signaling crossroads: The function of Raf kinase inhibitory protein in cancer, the central nervous system and reproduction. Cell Signal. 2008;20:1-9. (Pubitemid 350138364)
33. Wang CY, Liang YJ, Lin YS, Shih HM, Jou YS, Yu WC. YY1AP, a novel co-activator of YY1. J Biol Chem. 2004;279:17750-5. (Pubitemid 38560541)
34. Ohtomo T, Horii T, Nomizu M, Suga T, Yamada J. Molecular cloning of a structural homolog of YY1AP, a coactivator of the multifunctional transcription factor YY1. Amino Acids. 2007;33:645-52. (Pubitemid 350165434)
35. Klar M, Bode J. Enhanceosome formation over the beta interferon promoter underlies a remote-control mechanism mediated by YY1 and YY2. Mol Cell Biol. 2005;25:10159-70. (Pubitemid 41572760)
36. Kim JD, Faulk C, Kim J. Retroposition and evolution of the DNAbinding motifs of YY1, YY2 and REX1. Nucleic Acids Res. 2007;35: 3442-52. (Pubitemid 47073605)
37. Yeung KC, Rose DW, Dhillon AS, Yaros D, Gustafsson M, Chatterjee D, McFerran B, Wyche J, Kolch W, Sedivy JM. Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol. 2001;21:7207-17. (Pubitemid 32953475)
38. Eves EM, Shapiro P, Naik K, Klein UR, Trakul N, Rosner MR. Raf kinase inhibitory protein regulates aurora B kinase and the spindle checkpoint. Mol Cell. 2006;23:561-74. (Pubitemid 44205493)
39. Chatterjee D, Bai Y, Wang Z, Beach S, Mott S, Roy R, Braastad C, Sun Y, Mukhopadhyay A, Aggarwal BB, Darnowski J, Pantazis P, Wyche J, Fu Z, Kitagwa Y, Keller ET, Sedivy JM, Yeung KC. RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem. 2004;27:17515-23. (Pubitemid 38560515)
40. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non- Hodgkin's lymphoma: Implications in chemosensitization and therapeutic intervention. Oncogene. 2005;24:2121-43. (Pubitemid 40516580)
41. Bonavida B, Baritaki S, Huerta-Yepez S, Vega MI, Chatteriee D, Yeung K. Novel therapeutic applications of nitric oxide donors in cancer: Roles in chemo- and immunosensitization to apoptosis and inhibition of metastases. Nitric Oxide. 2008;19:152-7.
42. Baritaki S, Katsman A, Chatterjee D, Yeung KC, Spandidos DA, Bonavida B. Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation. J Immunol. 2007;179:5441-53.
43. Pilarsky C, Wenzig M, Specht T, Saeger HD, Grützmann R. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia. 2004;6:744-50. (Pubitemid 40041492)
44. Huerta-Yepez S, Vega M, Hernandez-Cueto A, Sanchez-Arellano B, Gordon S, Mizutani Y, Seligson D, Bonavida B. Nuclear expression of the transcription factor yin yang 1 (YY1) in hepatocellular carcinoma (HCC): Prognostic significance. AACR Meeting Abstracts. 2006: 215-6.
45. Schuierer MM, Bataille F, Weiss TS, Hellerbrand C, Bosserhoff AK. Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. Oncol Rep. 2006;16:451-6.
46. Lee HC, Tian B, Sedivy JM, Wands JR, Kim M. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology. 2006;131:1208-17. (Pubitemid 44498689)
47. Palko L, Bass HW, Beyrouthy MJ, Hurt MM. The Yin Yang-1 (YY1) protein undergoes a DNA-replication-associated switch in localization from the cytoplasm to the nucleus at the onset of S phase. J Cell Sci. 2004;117:465-76. (Pubitemid 38181208)
48. Nakanishi-Matsui M, Hayashi Y, Kitamura Y, Koike K. Integrated hepatitis B virus DNA preserves the binding sequence of transcription factor Yin and Yang 1 at the virus-cell junction. J Virol. 2000;74: 5562-8. (Pubitemid 30346590)
49. Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, Zhuang SM. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 2009;69: 1135-42.
50. Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Sunakozaka H, Sakai Y, Horimoto K, Kaneko S. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology. 2009;49:1098-12.
51. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J, Cheng A, Hall BM, Qualman SJ, Chandler DS, Croce CM, Guttridge DC. NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell. 2008;14:369-81.
52. Wang ZX, Wang HY, Wu MC. Identification and characterization of a novel hepatocellular carcinoma-associated gene. Br J Cancer. 2001;85:1162-7.
53. Li L, Shi Y, Wu H, Wan B, Li P, Zhou L, Shi H, Huo K. Hepatocellular carcinoma-associated gene 2 interacts with MAD2L2. Mol Cell Biochem. 2007;304:297-304. (Pubitemid 47456878)
54. Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, Takase K, Moriyama M, Kawano H, Hayashida M, Nakano T, Suzuki A. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology. 2000;31:1080-5. (Pubitemid 30233232)
55. Ikeguchi M, Hirooka Y, Kaibara N. Quantitative analysis of apoptosis- related gene expression in hepatocellular carcinoma. Cancer. 2002;95:1938-45. (Pubitemid 35222174)
56. Fields AC, Cotsonis G, Sexton D, Santoianni R, Cohen C. Survivin expression in hepatocellular carcinoma: Correlation with proliferation, prognostic parameters, and outcome. Mod Pathol. 2004;17:1378-85. (Pubitemid 39472993)
57. Notarbartolo M, Cervello M, Giannitrapani L, Meli M, Poma P, Dusonchet L, Montalto G, D'Alessandro N. Expression of IAPs and alternative splice variants in hepatocellular carcinoma tissues and cells. Ann NY Acad Sci. 2004;1028:289-93. (Pubitemid 40361830)
58. Takashima H, Nakajima T, Moriguchi M, Sekoguchi S, Nishikawa T, Watanabe T, Katagishi T, Kimura H, Minami M, Itoh Y, Kagawa K, Okanoue T. In vivo expression patterns of survivin and its splicing variants in chronic liver disease and hepatocellular carcinoma. Liver Int. 2005;25:77-84. (Pubitemid 40298248)
59. Montorsi M, Maggioni M, Falleni M, Pellegrini C, Donadon M, Torzilli G, Santambrogio R, Spinelli A, Coggi G, Bosari S. Survivin gene expression in chronic liver disease and hepatocellular carcinoma. Hepatogastroenterology. 2007;54:2040-4.
60. Chau GY, Lee AF, Tsay SH., Ke YR, Kao HL., Wong FH., Tsou AP, Chau YP. Clinicopathological significance of survivin expression in patients with hepatocellular carcinoma. Histopathology. 2007;51:204-18. (Pubitemid 47083982)
61. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP, Anderson KC. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: Therapeutic applications. Blood. 2002;99:4079-86. (Pubitemid 35332050)
62. Kawakami H, Tomita M, Matsuda T, Ohta T, Tanaka Y, Fujii M, Hatano M, Tokuhisa T, Mori N. Transcriptional activation of survivin through the NF-kB pathway by human T-cell leukemia virus type I tax. Int J Cancer. 2005;116:967-74. (Pubitemid 40791839)
63. Lee JS, Galvin KM, Shi Y. Evidence for physical interaction between the zinc-finger transcription factors YY1 and Sp1. Proc Natl Acad Sci USA. 1993;90:6145-9. (Pubitemid 23191471)
64. Xu R, Zhang P, Huang J, Ge S, Lu J, Qian G. Sp1 and Sp3 regulate basal transcription of the survivin gene. Biochem Biophys Res Commun. 2007;356:286-92. (Pubitemid 46413162)
65. Minoo P, Zlobec I, Baker K, Tornillo L, Terracciano L, Jass JR, Lugli A. Loss of raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer. Am J Clin Pathol. 2007;127:820-7.
66. Al-Mulla F, Hagan S, Al-Ali W, Jacob SP, Behbehani AI., Bitar MS., Dallol A, Kolch W. Raf kinase inhibitor protein: Mechanism of loss of expression and association with genomic instability. J Clin Pathol. 2008;61:524-9. (Pubitemid 351518239)
67. Hongo F, Garban H, Huerta-Yepez S, Vega M, Jazirehi AR, Mizutani Y, Miki T, Bonavida B. Inhibition of the transcription factor Yin Yang 1 activity by S-nitrosation. Biochem Biophys Res Commun. 2005;336:692-701. (Pubitemid 41267281)
68. Wu JM, Sheng H, Saxena R, Skill NJ, Bhat-Nakshatri P, Yu M, Nakshatri H, Maluccio MA. NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Lett. 2009;278:145-55.
69. Poma P, Notarbartolo M, Labbozzetta M, Sanguedolce R, Alaimo A, Carina V, Maurici A, Cusimano A, Cervello M, D'Alessandro N. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin on human hepatic cancer cells: Analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production. Int J Oncol. 2006;28:923-30.
70. Simoni D, Rizzi M, Rondanin R, Baruchello R, Marchetti P, Invidiata FP, Labbozzetta M, Poma P, Carina V, Notarbartolo M, Alaimo A, D'Alessandro N. Antitumor effects of curcumin and structurally betadiketone modified analogs on multidrug resistant cancer cells. Bioorg Med Chem Lett. 2008;18:845-9.